Pharmaceuticals News & Press Release Distribution

From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery

SHANGHAI, May 27, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated Screening & Chemistry." Moderated by Victoria Ouroutzoglou, Associate Director of Business Development...

2026-05-27 20:00 4139

From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery

SHANGHAI, May 27, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated Screening & Chemistry." Moderated by Victoria Ouroutzoglou, the roundtable featured Dr. Bing Xia, Vice...

2026-05-27 20:00 4613

Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer

SHANGHAI, May 27, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) h...

2026-05-27 18:40 5020

Fosun International Recognized on Fortune's 2026 "Most Admired Chinese Companies" List

HONG KONG, May 27, 2026 /PRNewswire/ -- On 27 May 2026, Fortune China magazine released its 2026 list of "Most Admired Chinese Companies", in which Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the Industry Star List. This highlights...

2026-05-27 17:43 5725

WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities

SHANGHAI, May 27, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Drug Product Facility 15 (DP15), located at the company's Fengxian site in Shanghai, achieved GMP release in April. The facil...

2026-05-27 17:14 6073

CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity

Acquisition strengthens U.S. peptide manufacturing capabilities and broadens global expertise in complex peptide APIs * CordenPharma has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide CDMO with facilities in North Augusta, South Carolina (USA) and Shanghai (China...

2026-05-27 13:00 4232

CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity

Neurophet Launches Joint Study with VHIR on 'Neurophet AQUA MS', Accelerating AI Algorithm Validation

* Collaborative research on AI-based diagnosis of multiple sclerosis, Building a clinical trial dataset * Leveraging large-scale, multi-center brain MRI datasets to detect key lesion biomarkers SEOUL, South Korea, May 26, 2026 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon ...

2026-05-26 21:00 6372

Neurophet Launches Joint Study with VHIR on 'Neurophet AQUA MS', Accelerating AI Algorithm Validation

Deepening Focus on Autoimmune Diseases, Empowering AI-Driven Drug Discovery

HkeyBio Builds a High-Efficiency Wet-Lab Validation Engine with Comprehensive CRO Service Upgrades in 2026 BOSTON and SUZHOU, China, May 26, 2026 /PRNewswire/ -- I. Industry Background: AI-Driven Drug Discovery Fuels Explosive Demand for Wet-Lab Validation, Creating New Opportunities for Specia...

2026-05-26 20:30 4001

SK bioscience Signs Vaccine Technology Transfer Agreement with Colombia's VECOL to Advance Local Vaccine Manufacturing in Latin America

* SK bioscience collaborates with Colombia's government-led US$260 million vaccine localization initiative through technology transfer and local manufacturing cooperation with state-owned pharmaceutical company VECOL * This alliance enables SK bioscience to enter Latin America by manufacturing...

2026-05-26 20:00 5874

SK bioscience Signs Vaccine Technology Transfer Agreement with Colombia's VECOL to Advance Local Vaccine Manufacturing in Latin America

Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine

* Approval granted by South Korea's Ministry of Food and Drug Safety (MFDS) * Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the preventive treatment of migraine in adults * Authorization supported by the Phase 3 SUNRISE trial conducted in a predominant...

2026-05-26 14:38 4322

Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

* Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients. * Data from the elacestrant plus capivasertib regimen of the ELEVATE study will be presented underscoring its potential i...

2026-05-25 18:56 5968

Informa Markets Puts Bangkok at the Center of Southeast Asia's Pharma Industry, Uniting 400 Exhibitors, Experts from 70 Countries at CPHI South East Asia

The Region's Premier Pharma Exhibition Returns to Bangkok, Elevating Thailand's Role in the ASEAN Pharmaceutical Supply Chain BANGKOK, May 24, 2026 /PRNewswire/ -- Informa Markets sets to organise CPHI South East Asia from 8–10 July 2026 at Queen Sirikit National Convention Center under the them...

2026-05-24 13:00 4779

Informa Markets Puts Bangkok at the Center of Southeast Asia's Pharma Industry, Uniting 400 Exhibitors, Experts from 70 Countries at CPHI South East Asia

Meet Clicklinks: The Innovation Hub for Original Drug Discovery

SHANGHAI, May 23, 2026 /PRNewswire/ -- For many participants in the innovative drug discovery arena, AI-STAL and SAI-DA are already familiar names within the Sanyou Bio ecosystem. AI-STAL is recognized as the "Grand Master Librarian" safeguarding a Super Trillion Antibody Library, while SAI-DA is...

2026-05-23 22:00 4430

Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations

SHANGHAI, May 21, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present multiple clinical study results of its novel Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) at the 2026 American S...

2026-05-22 11:30 6418

Nuance Pharma Announces IND Clearance for Actair® Pivotal Clinical Trial in China

NMPA Approval Marks Key Milestone in Advancing House Dust Mite Allergy Immunotherapy to Chinese Patients SHANGHAI, May 22, 2026 /PRNewswire/ -- Nuance Pharma today announced that the National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application, enabl...

2026-05-22 09:50 4330

Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026

* Sacituzumab tirumotecan (sac-TMT)(佳泰莱®) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced NSCLC: Results from the randomized, controlled, registrational Phase III OptiTROP-Lung05 study (Abstract #8506) * Efficacy and safety of lunbotinib fumarate (A...

2026-05-22 08:00 6449

Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting

TAIPEI, May 21, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. announces that its abstract highlighting the differentiated binding profile and preclinical efficacy ofTSY-310, a novel bispecific antibody-drug conjugate (ADC), has been selected for presentation at the American Society of Clinic...

2026-05-22 05:34 4527

Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS

CHENGDU, China, May 21, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Breast03) of the Company's tropho...

2026-05-21 22:08 7500

Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL

Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations GUANGZHOU, China and SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- Lupeng Pharmaceutical Ltd, a global clinical-stage biopharmaceu...

2026-05-21 22:00 5922

Hyundai Bioscience Discloses XAFTY®'s IC50 Data for Ebola--"Secured Scientific Evidence for Immediate Treatment"

* Ebola IC50 (0.125μM)—Strong inhibition at less than half the concentration of the clinically-tested COVID-19 (0.28μM). * Clinical safety confirmed through COVID-19 and Dengue clinical trials. * Class-wide efficacy proven by accumulated research data for Hantavirus treatment. * Davey Smit...

2026-05-21 08:38 4464